Back to results
US 11,040,095 B2Granted
Human rhinovirus vaccine
AssigneeGlaxosmithkline Biologicals SA
InventorsCatherine Marie Ghislaine Gerard, Sandra Giannini, Julien Thierry Massaux
Life of this patent
Estimating the term…
Abstract
HRV VP2 proteins useful as components of immunogenic compositions for the induction of cross-reactive cell-mediated immunity against human rhinovirus infection; nucleic acid constructs encoding such HRV VP2 proteins.
Claims15
An immunogenic composition comprising a human rhinovirus (HRV) VP2 protein and an adjuvant comprising a saponin, wherein the saponin is 40-60 μg per dose of the adjuvant composition, wherein the HRV VP2 protein is SEQ ID NO:1.
Dependencies are inferred from the claim text.